Emgality 120 mg solution for injection
*Company:
Eli Lilly and Company (Ireland) LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 24 October 2025
File name
Emgality_SmPC_Oct25_IE-MT.pdf
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated EMA website link at end of SmPC
Updated on 24 October 2025
File name
Emgality_PIL_Oct25_IE-MT.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 05 September 2025
File name
Emgality_PIL_EM038_Jul24_IE-MT.pdf
Reasons for updating
- XPIL Updated
Updated on 04 September 2025
File name
Emgality_PIL_EM038_Jul24_IE-MT.pdf
Reasons for updating
- XPIL Created
Updated on 11 February 2025
File name
Emgality_PIL_EM038_Jul24_IE-MT.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 03 February 2025
File name
Emgality_PIL_EM038_Jul24_IE-MT.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 03 February 2025
File name
Emgality_SmPC_EM037_Sep23_IE-MT.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Improved presentation of SPC
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Emgality_pen_IFU_EM033_Sep2023_IE-NI-MT.pdf
Reasons for updating
- Replace File
Updated on 14 September 2023
File name
Emgality_SmPC_EM031_Sep23_IE-MT-NI.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.5 - Nature and contents of container
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 14 September 2023
File name
Emgality_PIL_EM032_Sep23_IE-NI-MT.pdf
Reasons for updating
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
- Correction of spelling/typing errors
File name
Emgality_pen_IFU_EM028_Oct22_IE-NI-MT.pdf
Reasons for updating
- Replace File
Updated on 09 November 2022
File name
Emgality_PIL_EM027_Oct22_IE-NI-MT.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Improved presentation of PIL
- Change to date of revision
Updated on 22 July 2022
File name
Emgality_SmPC_EM022_Jul22_IE-MT-NI.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 22 July 2022
File name
Emgality_PIL_EM021_Jul22_IE-NI-MT.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
File name
Emgality_pen_IFU_IE-NI-MT_Jul21.pdf
Reasons for updating
- Add New Doc
Updated on 03 May 2022
File name
Emgality_IE NI MT_SmPC_EM012.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 May 2022
File name
PIL_Emgality_Pen_IE-NI-MT.pdf
Reasons for updating
- New PIL for new product
Eli Lilly and Company (Ireland) Limited
 Limited.webp)
Address:
Lilly House, Basing View, Basingstoke, Hampshire, RG21 4FA, United KingdomMedical Information E-mail:
ukmedinfo@lilly.comTelephone:
+353 1 661 4377Website:
https://www.lilly.ie